| The “primary” antiphospholipid syndrome: major clinical and serological features RA ASHERSON, MA KHAMASHTA, J Ordi-Ros, RHWM DERKSEN, ... Medicine 68 (6), 366-374, 1989 | 1391 | 1989 |
| Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies HJ Out, CD Kooijman, HW Bruinse, RHWM Derksen European Journal of Obstetrics & Gynecology and Reproductive Biology 41 (3 …, 1991 | 382 | 1991 |
| A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization HJ Out, BMJL Mannaerts, SGAJ Driessen, HJT Coelingh Bennink Human Reproduction 10 (10), 2534-2540, 1995 | 300 | 1995 |
| A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies HJ Out, HW Bruinse, GCML Christiaens, M van Vliet, PG de Groot, ... American journal of obstetrics and gynecology 167 (1), 26-32, 1992 | 222 | 1992 |
| Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic … HJTC Bennink, BCJM Fauser, HJ Out, ... Fertility and Sterility 69 (1), 19-25, 1998 | 141 | 1998 |
| Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins HJ Out, SGAJ Driessen, BMJL Mannaerts, HJTC Bennink Fertility and sterility 68 (1), 138-142, 1997 | 131 | 1997 |
| Increasing the daily dose of recombinant follicle stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation HJ Out, DDM Braat, BME Lintsen, T Gurgan, O Bukulmez, O Gökmen, ... Human Reproduction 15 (1), 29-35, 2000 | 126 | 2000 |
| Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies HJ Out, BMJL Mannaerts, SGAJ Driessen, HJTC Bennink Human Reproduction Update 2 (2), 162-171, 1996 | 119 | 1996 |
| Prevalence of antiphospholipid antibodies in patients with fetal loss. HJ Out, HW Bruinse, GC Christiaens, M Van Vliet, JF Meilof, PG De Groot, ... Annals of the rheumatic diseases 50 (8), 553-557, 1991 | 97 | 1991 |
| Antibodies to platelets in patients with anti-phospholipid antibodies HJ Out, PG de Groot, M van Vliet, GC de Gast, HK Nieuwenhuis, ... | 85 | 1991 |
| Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. HJ Out, PG de Groot, P Hasselaar, M dan Vliet, RH Derksen Annals of the rheumatic diseases 48 (12), 1023-1028, 1989 | 83 | 1989 |
| Efficacy and safety of recombinant follicle stimulating hormone (Puregon®) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a … B Hedon, HJ Out, JN Hugues, B Camier, J Cohen, P Lopes, JR Zorn, ... Human Reproduction 10 (12), 3102-3106, 1995 | 80* | 1995 |
| Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy BMJL Mannaerts, F Rombout, HJ Out, HC Bennink Human reproduction update 2 (2), 153-161, 1996 | 79 | 1996 |
| Role of editorial and peer review processes in publication bias: analysis of drug trials submitted to eight medical journals M van Lent, J Overbeke, HJ Out PloS one 9 (8), e104846, 2014 | 76 | 2014 |
| A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women … HJ Out, S Lindenberg, AL Mikkelsen, T Eldar-Geva, DL Healy, A Leader, ... Human Reproduction 14 (3), 622-627, 1999 | 75 | 1999 |
| A randomized, double‐blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for … HJ Out, A Rutherford, R Fleming, CCK Tay, G Trew, W Ledger, D Cahill Human Reproduction 19 (1), 90-95, 2004 | 74 | 2004 |
| A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles HJ Out, I David, R Ron-El, S Friedler, E Shalev, J Geslevich, J Dor, ... Human Reproduction 16 (6), 1104-1109, 2001 | 74 | 2001 |
| A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in … CA Jansen, HC van Os, HJ Out, HJ Coelingh Bennink Human reproduction (Oxford, England) 13 (11), 2995-2999, 1998 | 72 | 1998 |
| The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments D Sykes, HJ Out, SJ Palmer, J Loon Human Reproduction 16 (12), 2557-2562, 2001 | 71 | 2001 |
| Drug delivery system RJJ Groenewegen, W De Graaff, HJ Out US Patent 8,333,983, 2012 | 69 | 2012 |
